NASDAQ : CURX
Curanex Pharmaceuticals Inc — Key statistics
Healthcare · Biotechnology · United States
Last price 4.75 USD (At close: Aug 25, 2026) · Market cap 7.45M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 7.45M |
| Enterprise Value | 4.79M |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.57M |
| Shares Outstanding | 1.57M |
| Shares Change (YoY) | +15.03% |
| Shares Change (QoQ) | +1,901.43% |
| Owned by Insiders (%) | 61.28% |
| Owned by Institutions (%) | 1.12% |
| Float | n/a |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.41 |
| P/TBV Ratio | 1.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 45.95 |
| Quick Ratio | 28.17 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,580.17 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -411.08% |
| Return on Assets (ROA) | -225.06% |
| Return on Invested Capital (ROIC) | -225.65% |
| Return on Capital Employed (ROCE) | -212.35% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.74M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 4.62 |
| 200-Day Moving Average | 7.11 |
| Relative Strength Index (RSI) | 54.44 |
| Average Volume (20 Days) | 21,181 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 12,389 |
| Short Previous Month | 11,829 |
| Short % of Shares Out | 0.79% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.17 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -7.84M |
| Operating Income | -10.55M |
| Pretax Income | -10.47M |
| Net Income | -10.47M |
| EBITDA | n/a |
| EBIT | -10.55M |
| Earnings Per Share (EPS) | -$7.57 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 2.94M |
| Total Debt | 276,359 |
| Net Cash | 2.66M |
| Net Cash Per Share | $1.70 |
| Equity (Book Value) | 4.79M |
| Book Value Per Share | 3.38 |
| Working Capital | 4.69M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -12.08M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 121,410 |
| Net Borrowing | -400,000 |
| Free Cash Flow | -12.08M |
| FCF Per Share | -$7.70 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -15.03% |
| Shareholder Yield | -15.03% |
| Earnings Yield | -140.53% |
| FCF Yield | -162.15% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 20, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |